Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update
- Jeffrey J. Link
- , John J. Warner
- , James A. de LemosAffiliated withUniversity of Texas Southwestern Medical Center Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Based on important studies published in the past year, the role of low-molecular-weight heparin in acute coronary syndromes and percutaneous coronary interventions has continued to evolve. For patients with non-ST-elevation acute coronary syndromes, several alternatives to enoxaparin have been introduced, including fondaparinux and bivalirudin. In patients with ST-elevation myocardial infarction, recent studies have demonstrated a clear mortality benefit from adjunctive antithrombin therapy and the superiority of a prolonged course of enoxaparin over a standard duration of unfractionated heparin. Furthermore, recent data have demonstrated the safety of enoxaparin as an alternative to unfractionated heparin among patients undergoing percutaneous coronary interventions.
- Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update
Current Cardiovascular Risk Reports
Volume 1, Issue 4 , pp 303-309
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links